Crescent Biopharma, Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| CBIO | LLY | |
|---|---|---|
| Market Cap | $622.95 million | $1.01 trillion |
| Revenue (TTM) | $119.38 million | $79.67 billion |
| Net Income (TTM) | $-20,897,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| CBIO | LLY | |
|---|---|---|
| P/E Ratio | — | 38.48 |
| Price / Book | 4.37 | 29.94 |
| Price / Sales | 5.22 | 12.73 |
CBIO leads on 2 of 2 valuation factors.
Profitability
| CBIO | LLY | |
|---|---|---|
| Net Margin | -17.50% | 33.53% |
| Return on Equity | -14.67% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| CBIO | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
| Payout Ratio | — | 23.23 |
CBIO and LLY split the dividend factors evenly.
Risk & Sentiment
| CBIO | LLY | |
|---|---|---|
| Short Interest | 1.64% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: CBIO overview, CBIO financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.